Comparative Efficacy and Safety of the Artemisinin Derivatives in Severe Malaria treatment; a network meta-analysis (Data)

Introduction This data was produced for a systematic review update and Network Meta-analyses (NMA) which was conducted according to the PRISMA guidelines extension. The NMA protocol was registered with PROSPERO registration number CRD42020218190 . Our objective was to evaluate the efficacy and safety of the artemisinin derivatives and quinine for treating severe Plasmodium falciparum malaria. Outcomes Assessed Outcomes have pharmacological and clinical relevance. Primary Outcome 1. Mortality. The proportion of death from all causes was compared between all interventions from onset of treatment. Secondary Outcomes 1. Neurological Sequela Events among survivors The proportion of patients developing neurological sequela was evaluated among those who survived. Subgroup analyses included time-point of neurological sequela assessment (acute vs persistent). 2. Coma Recovery time Mean time in hours from start of treatment to coma recovery was compared among interventions. 3. Parasite Clearance time The mean time in hours from initial administration of antimalarial absence of malaria parasites in blood-film was compared between treatments. 4. Fever Clearance Time The mean time in hours from initial administration of antimalarial to consecutive normothermia (defined in some studies as < 37.5 Degrees Celsius) was compared between treatments. 5. Adverse events The proportion of patients experiencing adverse events after treatment was initiated was compared. Both specific events and composite measures were explored. The most frequently reported adverse events were included in the NMA and the others were reported in a table as number of events and proportion experiencing the event. Data was prepared suitable for NMA random effect model in a frequentist framework using R (version 3.6.0) netmeta package (version 1.2-1). R script for the analyses can be found in the following link; https://github.com/nyaaba-nick/A-Comparative-Efficacy-and-Safety-of-the-Artemisinin-Derivatives-a-Network-Meta-Analyses-R-Script-

本数据集为遵循PRISMA扩展指南（PRISMA Guidelines Extension）开展的系统评价更新及网状Meta分析（Network Meta-analyses, NMA）所生成。本NMA研究方案已在PROSPERO国际系统评价前瞻性注册库（International Prospective Register of Systematic Reviews）注册，注册号为CRD42020218190。本研究旨在评估青蒿素衍生物与奎宁治疗重症恶性疟原虫疟疾的疗效与安全性。
评估指标 本研究的评估指标兼具药理学与临床相关性。
主要结局指标 1. 死亡率：对比各干预措施自治疗启动起的全因死亡比例。
次要结局指标 1. 幸存者神经系统后遗症：对存活患者中出现神经系统后遗症的比例进行评估。亚组分析涵盖神经系统后遗症评估的时间节点（急性期vs持续性后遗症）。2. 昏迷恢复时间：对比各干预措施中，从治疗开始至昏迷恢复的平均小时数。3. 寄生虫清除时间：对比各治疗方案中，从首次给予抗疟药物至血涂片疟原虫转阴的平均小时数。4. 退热时间：对比各治疗方案中，从首次给予抗疟药物至连续体温正常（部分研究定义为体温＜37.5摄氏度）的平均小时数。5. 不良事件：对比各干预措施中，启动治疗后出现不良事件的患者比例。本研究同时考察了特异性不良事件与复合结局指标。网状Meta分析纳入了报告频次最高的不良事件，其余不良事件则以事件发生数与事件发生率的形式汇总于表格中。
本数据集已完成预处理，适配基于频率学派框架的网状Meta分析随机效应模型，使用R软件（版本3.6.0）及netmeta包（版本1.2-1）完成。本研究分析所用的R脚本可通过以下链接获取：https://github.com/nyaaba-nick/A-Comparative-Efficacy-and-Safety-of-the-Artemisinin-Derivatives-a-Network-Meta-Analyses-R-Script-